Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Musto

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2011
Primary plasma cell leukemia: a retrospective multicenter study of 73 patientsL Pagano, C G Valentini, V De Stefano, et al.
Leukemia Research|January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome predictionF Ramos, S Thépot, L Pleyer, et al.
Oncogene|October 4, 2011
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targetsS Berardi, A Caivano, R Ria, et al.
Leukemia|December 22, 2017
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myelomaS Bringhen, M D'Agostino, L De Paoli, et al.
Scientific Reports|February 8, 2020
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signalingA Romano, N L Parrinello, V Simeon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2013
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana LinfomiS Luminari, I Biasoli, L Arcaini, et al.
Leukemia Research|February 21, 2023
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapyL Maurillo, A Spagnoli, A Candoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2014
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)S Luminari, I Biasoli, A Versari, et al.
Leukemia|September 22, 2012
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patientsP Falco, F Cavallo, A Larocca, et al.
Leukemia|June 4, 2011
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapyF Cavallo, S Bringhen, G Milone, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2011
Primary plasma cell leukemia: a retrospective multicenter study of 73 patientsL Pagano, C G Valentini, V De Stefano, et al.
Leukemia Research|January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome predictionF Ramos, S Thépot, L Pleyer, et al.
Oncogene|October 4, 2011
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targetsS Berardi, A Caivano, R Ria, et al.
Leukemia|December 22, 2017
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myelomaS Bringhen, M D'Agostino, L De Paoli, et al.
Scientific Reports|February 8, 2020
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signalingA Romano, N L Parrinello, V Simeon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2013
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana LinfomiS Luminari, I Biasoli, L Arcaini, et al.
Leukemia Research|February 21, 2023
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapyL Maurillo, A Spagnoli, A Candoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2014
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)S Luminari, I Biasoli, A Versari, et al.
Leukemia|September 22, 2012
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patientsP Falco, F Cavallo, A Larocca, et al.
Leukemia|June 4, 2011
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapyF Cavallo, S Bringhen, G Milone, et al.
Pageof 12